<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109041</url>
  </required_header>
  <id_info>
    <org_study_id>CT005</org_study_id>
    <nct_id>NCT03109041</nct_id>
  </id_info>
  <brief_title>Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source</brief_title>
  <official_title>Initial Feasibility Study to Treat Resectable Pancreatic Cancer With the Permanently Implantable LDR CivaSheetÂ®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that
      utilizes active components (Palladium-103) of standard devices in a novel configuration. This
      study may benefit resectable pancreatic cancer patients by reducing the radiation dose to
      adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at
      a surgical margin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale</measure>
    <time_frame>1.5 years</time_frame>
    <description>Patients with resectable pancreatic cancer who are undergoing the Whipple procedure will be monitored for safety &amp; toxicities graded using the CTCAE 4.0 scale.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Directional Brachytherapy Source Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CivaSheet</intervention_name>
    <description>The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.</description>
    <arm_group_label>Directional Brachytherapy Source Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject signed informed consent

          -  Age &gt;/= 18 years

          -  Biopsy confirmed adenocarcinoma pancreatic cancer

          -  Patient capable of undergoing anesthesia

          -  Patient is a surgical candidate

          -  Patient selected to undergo Whipple procedure

          -  Patient will have known or suspected close/positive surgical margin

          -  Confirmed diagnosis of resectable pancreatic adenocarcinoma

          -  Will be prescribed standard Gemcitabine 1000 mg/m2 chemotherapy cycle

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Patient has metastatic disease

          -  Patient has had prior radiation therapy to the region for separate cancer

          -  Patient has had prior chemotherapy

          -  Any other invasive cancer in the past 5 years, except basal cell skin

          -  Recurrent or previously resected tumors

          -  Alcoholism/Drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>9193145515</phone>
    <email>ccastagnero@tabclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Perez, PhD</last_name>
    <phone>6789545744</phone>
    <email>kperez@civatechoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>East Carolina University, Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Coghill</last_name>
      <phone>252-744-5723</phone>
      <email>COGHILLL@ECU.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Wetherington</last_name>
      <phone>252-744-5723</phone>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel Zervos</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Ju</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Whipple</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>CivaSheet</keyword>
  <keyword>CivaTech Oncology</keyword>
  <keyword>radiation</keyword>
  <keyword>intraoperative radiation</keyword>
  <keyword>IORT</keyword>
  <keyword>resectable pancreatic cancer</keyword>
  <keyword>Pd-103</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

